PPARγ Agonist Treatment for Cocaine Dependence

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Cocaine Use DisorderAlcohol Use Disorder
Interventions
DRUG

Pioglitazone

Subjects randomized to pioglitazone begin with a starting dose of 15 mg daily administered. The dose will be titrated up to 30mg on the second week and 45 mg on the third week of the study. Subjects will remain on 45 mg of pioglitazone until the end of week 12. At the end of week 12 the study medication will be discontinued.

DRUG

Placebo

Subjects randomized to placebo receive placebo capsules once daily across all twelve weeks of the study.

BEHAVIORAL

Therapy

Cognitive-behavioral therapy 1 hour per week

BEHAVIORAL

Contingency Management

Prize-based contingency management for attendance

Trial Locations (1)

77030

The University of Texas Health Science Center at Houston, Houston

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

The University of Texas Health Science Center, Houston

OTHER

NCT02774343 - PPARγ Agonist Treatment for Cocaine Dependence | Biotech Hunter | Biotech Hunter